Assessment of haemato-biochemical parameters and therapeutics on *Brucella* infected cattle

**Abstract**

Brucellosis is a contagious systemic bacterial disease of livestock. Antibiotics commonly being used have limited efficacy against the disease. In the present study, therapy with antibiotics on *Brucella* infected cattle was performed and subsequently haemato-biochemical parameters, detection of anti-*Brucella* antibodies in both serum and milk by different diagnostics and shedding of *Brucella* in milk were assessed. Treatment with antibiotics; streptomycin and long acting tetracycline alone and in combination were given for four weeks. Hb, TEC, TLC, neutrophils, eosinophils, lymphocytes, monocytes count, AST, ALT and SD values were lower whereas, PCV, serum glucose, total protein, albumin and creatinine were higher in *Brucella* infected cattle. Treatment with combination therapy showed promising results in these animals. Haemato-biochemical parameters were become near to normal in most of animals that received combination therapy. However, not all animals were returned to normal after treatment but a significant numbers in combination therapy were reduced anti-Brucella antibody titre, both in serum and milk. The level of as shedding of *Brucella* in milk had also gone undetectable.

**Keywords:** brucellosis, cattle, haemato-biochemical parameters, oxytetracycline, streptomycin

**Abbreviations:** RBPT, rose Bengal plate test; STAT, standard tube agglutination test; ABR, abortus bang ring; ELISA, enzyme linked immunosorbent assay; MRT, milk ring test; PCR: polymerase chain reaction; Hb: haemoglobin; PCV, packed cell volume; TEC, total erythrocytes count; TLC, total leucocytes count; DLC, differential leucocytes count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SD: sorbitol dehydrogenase; PD-ADMAS, project directorate on animal disease monitoring and surveillance; RAR, research animal resources.

**Introduction**

Brucellosis is a most common zoonosis in the world, caused by different *Brucella* species. In cattle, it is caused by *B. abortus*, also known as contagious abortion. In last trimester, birth of unthrifty newborn, retained placenta in female and orchitis, epididymitis in male animals are the common manifestations of brucellosis in animals and it may lead to temporary or permanent infertility. Diagnosis on the basis of abortion is, however, equivocal since many pathogens can induce abortion; thus laboratory testing is essential. Various tests viz; Rose Bengal Plate Test (RBPT), Standard Tube Agglutination Test (STAT), Enzyme Linked Immunosorbent Assay (ELISA) and Milk Ring Test (MRT) are commonly used for the detection of anti-*Brucella* antibody. Isolation of the causative agent is most accepted tool for confirmatory diagnosis, but it is time consuming and has reduced sensitivity in chronic stage of infection. Handling of suspected clinical samples will require containment level for group 3 pathogens. Numerous Polymerase Chain Reaction (PCR) based assays have been developed for the rapid identification of *Brucella*. It is advantageous to detect DNA of pathogen that rendered biologically safe and hence, reduced the risk of infection to laboratory workers. In addition, PCR is more sensitive than traditional culture method. There is limited evidence on treatment aspect of *Brucella* infected cattle as well as their haemato-biochemical parameters. *Brucella* is inaccessible to antibiotics as they are facultative intracellular pathogens. Many antimicrobials are active against *Brucella* species; however, clinical efficacy does not always correlate with *in vitro* susceptibility. Treatments for brucellosis have been tried previously but none was found successful. Streptomycin acts synergistically with penicillin or tetracycline to inhibit the growth of *B. abortus* within bovine cells cultured *in vitro*. Considering the above facts, the present work was intended to determine the efficacy of antibiotic therapy and alteration in the haemato-biochemical parameters if any, in *Brucella* infected cattle after treatment.

**Materials and methods**

A total of 27 cattle which showed antibodies both in serum and milk as well as *Brucella* DNA in milk were selected for the study. ELISA, RBPT and STAT were employed on serum whereas, MRT and ELISA on milk to detect the anti-*Brucella* antibodies. Milk samples were processed for detection of pathogen itself in form of its DNA (16S rRNA) by PCR. Reference antigens and serum for RBPT, STAT and, for MRT, Abortus Bang Ring Antigen (ABR Antigen) were procured from the Indian Veterinary Research Institute, Izatnagar (India). AmiGen *B. abortus* Ab ELISA kit (Cat. No. EB43-01) (i-ELISA and Milk-ELISA) was procured from Bionote (Korea). Haemato-biochemical parameters, antibody titre in milk/serum and shedding of pathogen in milk were evaluated before and after the therapeutic trial.

**Antibody detection**

RBPT was performed according to the method prescribed in OIE. Equal volume of both antigen and serum sample was mixed, definite agglutination was taken as positive whereas, no agglutination as negative. STAT was performed as per the method described by Alton et al. All serum samples were tested up to minimum of five dilutions. Considering the special significance of 50% end point, a control tube was set up to simulate 50% clearing by mixing 0.5 ml antigen with 1.5 ml of phenol saline (0.5%, v/v) in an agglutination tube. All tubes
were incubated at 37°C for 20 hrs before result was observed. The highest serum dilution showing 50% or more agglutination (50% clearing) was considered as the titre of the serum.

MRT was performed on individual milk samples according to the method described in OIE1. Dark pink ring above the white milk column was taken as positive whereas, pink colour of the underlying milk exceeds that of the cream layer as negative. i-ELISA and Milk-ELISA was performed by using AmiGen B. Brucella Ab ELISA kit. Method mentioned in manual provided with kit was followed. OD of ELISA plate was taken at 450nm to calculate the percent positivity (%P) of both serum and milk samples. Positive and negative samples were determined based on Percent positivity (%P) value. Sera which have %P value ≥25 were taken as positive whereas, samples having %P value <25 were negative. %P of serum was calculated from OD as follow:

\[
\% P = \frac{OD \text{ of serum sample}}{Average \text{ OD of standard positive control}} \times 100
\]

The milk samples gave %P value ≥15 were taken as positive whereas, samples with <15 %P value as negative. It was calculated as follows:

\[
\% P = \frac{OD \text{ of milk sample}}{Average \text{ OD of standard positive control milk}} \times 100
\]

Polymerase chain reaction

Specific DNA sequence of 905 bp, which belong to 16S rRNA of B. abortus,13 was targeted for amplification. Oligonucleotides (F:4'-5'TCGAGGCCCCGCAAGG-3' and R2: 5'-AACCATAAGTGTCCTCACTAAA-3') required for amplification of earlier said sequence were taken from published literature.13 Methods described for DNA extraction from milk16 and PCR14 were followed as mentioned in their respective literatures. Agarose gel (0.8% w/v in 0.5X Tris-borate EDTA) containing 0.5µg/ml ethidium bromide was used to electrophorese the amplified PCR products in 0.5X Tris-borate EDTA at 40 Volt/cm.

Haematological parameters; Haemoglobin (Hb), Packed Cell Volume (PCV), Total Erythrocytes Count (TEC), Total Leucocytes Count (TLC) and Differential Leucocytes Count (DLC) were estimated as methods described by Jain.11 Biochemical parameters; Glucose, Total Protein, Albumin, Creatinine, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Sorbitol Dehydrogenase (SD) were estimated in serum by commercially available kits (Span Diagnostics and Sigma).

Therapeutic trial

Cattle which had anti-Brucella antibodies both in serum and milk as well as presence of pathogen in milk were chosen for therapeutic trial. Three groups were formed; each contained nine cattle and maintained for 4 weeks. Long acting oxytetracycline at a dose rate of 25mg/kg intramuscularly, every other day for 4 weeks was given in Group A. Similarly, streptomycin at a dose rate of 20mg/kg intramuscularly, every other day for 4 weeks was given in Group B. While in Group C, long acting oxytetracycline at a dose rate 25mg/kg combined with streptomycin at a dose rate 20mg/kg were injected intramuscularly every other day for two weeks and further, oxytetracycline at the same dosage without streptomycin for two weeks. A control group of three animals, all were negative for anti-Brucella antibodies both in serum and milk as well as no pathogen found in milk were maintained for 4 weeks without any treatment given.

Statistical analysis

Statistical analysis between respective means for various parameters was performed using ANOVA and t-test, as per the method described by Snedecor & Cochran14 at 5% level of significance.

Results

Cattle found positive for antibodies both in serum and milk as well as presence of pathogen in milk were selected for the therapeutic trail. Treatment efficacies were evaluated on the basis of haemato-biochemical parameters, detection of antibodies both in milk and serum and shedding of pathogen in milk, before and after the treatments. Brucella infected cattle showed; lower Hb, TEC, TLC, neutrophils, eosinophils, lymphocytes and monocytes count whereas, PCV was higher than the respective value from control group (Table 1). The biochemical study in the Brucella infected cattle showed higher level of serum glucose, total protein, albumin and creatinine but, AST, ALT and SD values were lower than the respective value from control group (Table 2). Group A, which received long acting oxytetracycline treatment, showed significant increase in level (p<0.05) of Hb, lymphocyte and AST, whereas total protein, creatinine, albumin, ALT and SD were not significantly altered (p>0.05) after the treatment. Furthermore, five cattle reduced the shedding of pathogen to undetectable level in milk, as it was confirmed by PCR (Table 3). Similarly, STAT and ELISA were unable to detect anti-Brucella antibodies in serum samples of four and two animals, respectively after the treatment. Furthermore, five cattle not able to detect anti-Brucella antibodies in serum samples of four and two animals, respectively after the treatment. All the haematological and biochemical parameters under study were not altered significantly except TEC (p<0.05) (Table 1 & 2). In group C, there was reduction in anti-Brucella antibody level in serum and milk to such an extent, RBPT, STAT and ELISA were unable to detect respectively, in five, six and five animals (Table 3). Similarly, MRT and ELISA on milk from six and five animals were negative for antibody, respectively. Furthermore, six cattle shed undetectable amount of pathogen in milk, as it was confirmed by PCR (Table 3). Animals which had received combination therapy, significant increased its level (p<0.05) of Hb, TEC, TLC and lymphocytes counts (Table 1). However, alteration in PCV, neutrophils, eosinophils and monocytes count were non-significant (p>0.05). Biochemical parameters; glucose, total protein and albumin showed significant decrease (p<0.05) but, ALT, AST and SD increased significantly (p<0.05) after therapy (Table 2).
Table 1: Means of respective haematological parameter of animals from respective groups, before and after the therapeutic trial.

| Parameters          | Before treatment | After treatment |
|---------------------|------------------|-----------------|
|                     | Control (n=3)    | Group A (n=9)   | Group B (n=9) | Group C (n=9) | Control (n=3) | Group A (n=9) | Group B (n=9) | Group C (n=9) |
| Hb (g/L)            | 135.3±11.00     | 98±10.48a      | 99.5±9.78     | 99.5±10.38a                      | 144±08.70      | 99.5±10.50a | 105.1±10.95  | 116.5±14.16a |
| PCV (L/L)           | 0.38±0.61       | 0.39±0.02      | 0.4±0.02      | 0.39±0.02                        | 0.4±0.02       | 0.4±0.02   | 0.4±0.02     | 0.4±0.02     |
| TEC (X 10^3/L)      | 7.9±0.85        | 6.41±0.53      | 6.42±0.61b    | 6.37±0.69b                       | 7.96±0.75      | 6.4±0.52   | 6.51±0.63e   | 6.45±0.62e   |
| TLC (X 10^3/L)      | 8.2±0.56        | 3.26±0.24      | 3.35±0.29     | 3.85±0.09a                       | 8.26±0.51      | 3.27±0.25  | 3.38±0.25    | 4.16±0.11a   |
| Neutrophil (X 10^3/L)| 2.96±0.21   | 2.62±0.52      | 2.6±0.20      | 2.73±0.31                        | 3.03±0.31      | 2.67±0.47  | 2.62±0.19    | 2.7±0.32     |
| Eosinophil (X 10^3/L) | 1.06±0.15  | 0.84±0.11      | 0.88±0.16     | 0.85±0.12                        | 1.1±0.20       | 0.85±0.13  | 0.89±0.15    | 0.87±0.14    |
| Lymphocyte (X 10^3/L) | 3.63±0.38 | 1.97±0.40a     | 1.96±0.41     | 1.94±0.39a                       | 3.88±0.42      | 2.02±0.42  | 2±0.41       | 2.03±0.41    |
| Monocyte (X 10^3/L) | 0.3±0.10        | 0.15±0.03      | 0.15±0.03     | 0.158±0.03                       | 0.33±0.06      | 0.158±0.03 | 0.16±0.03    | 0.16±0.03    |

aFigures having same superscripts are significant at 5% level of significance for respective parameters, n, number of animals; Hb, haemoglobin; PCV, packed cell volume; TEC, total erythrocytes count; TLC, total leucocytes count; DLC, differential leucocytes count.

Table 2: Means of respective biochemical parameters of animals from respective groups, before and after the therapeutic trial.

| Parameters          | Before treatment | After treatment |
|---------------------|------------------|-----------------|
|                     | Control (n=3)    | Group A (n=9)   | Group B (n=9) | Group C (n=9) | Control (n=3) | Group A (n=9) | Group B (n=9) | Group C (n=9) |
| Glucose (mmol/L)    | 3.33±0.33        | 5.07±0.16       | 5.04±0.19     | 5.02±0.19a                      | 3.3±0.36       | 5.04±0.17   | 5.02±0.19    | 3.94±0.48a   |
| Total Protein (g/L) | 74.67±4.93       | 92.96±6.15      | 93.33±5.61    | 92.67±6.29a                     | 74.43±4.89     | 92.46±6.07  | 93.05±5.90  | 64.33±6.59a  |
| Albumin (g/L)       | 29.2±6.5         | 37.77±1.07      | 38.53±0.80    | 39.03±0.98a                      | 28.78±2.55     | 37.31±1.32  | 37.99±0.84  | 28.3±2.55    |
| Creatinine (µmol/L) | 102.67±35.22     | 179.24±19.47    | 179.53±20.25  | 180.65±20.36                     | 102.74±34.26   | 178.5±19.41 | 178.6±19.41 | 180.24±20.11 |
| ALT (units/L)       | 15.26±3.24       | 7±2.10          | 6.7±1.84      | 6.35±2.04a                       | 15.9±2.82      | 7.16±1.06   | 6.78±1.57   | 14.98±2.42   |
| AST (units/L)       | 91.3±4.53        | 61.53±7.73a     | 60.88±8.84    | 59.73±8.50a                      | 91.99±4.57     | 62.04±7.86  | 61.49±8.84  | 101.18±18.02 |
| SD (units/L)        | 9.9±1.25         | 2.92±0.33       | 2.82±0.27     | 2.75±0.32                        | 9.93±1.10      | 2.95±0.30   | 2.85±0.28   | 6.47±0.50    |

aFigures having same superscripts are significant at 5% level of significance for respective parameters, n, number of animals; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SD, sorbitol dehydrogenase.

Table 3: Number of cattle remains positive for concerned attributes in respective diagnostics after the therapeutic trial.

| Tests            | Group A (n=9) | Group B (n=9) | Group C (n=9) |
|------------------|---------------|---------------|---------------|
| RBPT             | 6             | 6             |               |
| STAT             | 5             | 6             | 3             |
| i-ELISA (on serum) | 7             | 7             | 4             |
| MRT              | 4             | 4             | 3             |
| Milk-ELISA       | 6             | 5             | 4             |
| PCR on milk      | 4             | 4             | 3             |

N, number of animals; RBPT, rose Bengal plate test; STAT, standard tube agglutination test; i-ELISA, indirect-enzyme-linked immunosorbent assay; MRT, milk ring test; ELISA, enzyme linked immunosorbent assay; PCR, polymerase chain reaction.

Discussion

Brucellosis has wide socio-economic impact, especially in countries in which rural income relies largely on animal husbandry.\textsuperscript{19,20} In India, it causes approximately Rs. 350 million economic losses.\textsuperscript{21} Several studies have confirmed widespread prevalence in different States of India.\textsuperscript{22-25} High seroprevalence has been reported in Indian dairy herds.\textsuperscript{26,27} Long-term serological studies at national level indicated, 5% cattle infected with brucellosis.\textsuperscript{28} Despite the advances made in the diagnosis, vaccination and therapy to control the disease, it is still wide spread and prevalent in many developing countries. There are limited researches on treatment and haemato-biochemical parameters of infected animals. Lowered haematological values such as Hb, TEC, TLC, neutrophils, eosinophils, lymphocytes and monocytes counts were recorded in the present study. Most of earlier studies didn’t explore the all haematological parameters in \textit{Brucella}.
infected animals. RAR⁵⁹ reported lower Hb value than the reference value in the Brucella infected cattle. Intra-cellular position of the Brucella spp. might cause reduction of Hb percentage.⁵⁰ Animals such as moose, infected experimentally with B. abortus showed slight lower Hb concentration.²⁸ or within the range of reference value.²⁹ Some worker has also reported higher Hb concentration in Brucella infected animals.²³ Lympocyte count was also lowered in Brucella infected animals.²³,³³ However, Sikder et al.,³⁶ found higher values of neutrophil, monocyte and eosinophil counts in the B. abortus positive cattle than the standard values.

He also found Hb, PCV, TEC, TLC, lymphocytes and basophils values of infected cattle within the reference range. Lymphoid depletion in the thymic cortex in natural and experimental could give lymphopenic condition.³³ Biochemical parameters such as serum glucose, serum total protein, serum albumin, and creatinine, revealed higher value in infected cattle but, other parameter such as AST, ALT and SD were lower than the reference value in the present study. El-Boshy et al.,³² reported significant increases (P<0.05) in serum SD, AST and ALT levels and non-significant-variations in creatinine in Brucella infected animals. Forbes et al.,³² confirmed stable and similar haemato-biochemical parameters in moose experimentally infected with B. abortus biovar 1. Several treatment trials for brucellosis have been previously attempted, but none was entirely successful. The Brucella bacterium is protected from antibiotics since it survives within phagoeyctic cells of the reticuloendothelial system. Successful treatment needs permeability of drug across the cell wall of bacterium. Present therapeutic trial on Brucella infected cattle showed; long acting oxytetracycline and streptomycin combination gave better results than the drugs given alone. However, they did not cure infection completely.

Animals either stopped shedding of pathogen or reduced its level to such an extent to diagnose by test implied. Similarly, antibody level in some of animals reduced to such a level as it was undiagnosed by different diagnostics used both on serum and milk. Oxytetracycline and streptomycin are capable of penetrating the bacterial cell wall, inhibiting protein synthesis and providing long lasting concentrations in the plasma and hence considered most effective in the treatment of brucellosis.³⁴ Combination of both has demonstrated synergistic effect in vitro.³² Long term treatment with high doses of oxytetracycline and streptomycin combination in Brucella infected Neumann’s gazelles resulted in eradication of the infection.³⁵ But, relapse and abortion were noticed frequently in animals which received antibiotic treatments.³⁶,³⁷ Streptomycin-tetracycline could be the choice of therapy for brucellosis, particularly in severe cases.³⁸ Combination therapy of long acting oxytetracycline and streptomycin revealed a significant increase (p<0.05) in Hb, TEC, TLC, lymphocytes count, ALT, AST and SD and significant decrease (p<0.05) in the values of glucose, total protein and albumin and non-significant alteration (p>0.05) in other parameters. Omer et al.,³⁷ found significant changes in Hb, ALT and glucose, after combination therapy in Brucella infected gazelles. But changes in other haemato-biochemical parameters following the treatment were non-significant.

**Conclusion**

Long acting oxytetracycline and streptomycin in combination could be used for treatment of Brucella infected cattle, but it needs further validation. Shedding of pathogen in milk or other body secretions of animal should be monitored for longer duration, not only by PCR but also by isolation of bacterium on suitable media. Relapse of infection or abortion in subsequent pregnancy should also be monitor to validate the treatments. Use of haemato-biochemical parameters as indicator of Brucella infection is not warranted, as alterations in these parameters are also evidenced in other bacterial infections. Therefore, these alterations should be carefully interpreted to give a final decision. It is better to complement a serological or molecular test to attain a final conclusion.

**Acknowledgments**

The authors are thankful to the Dean Post Graduate Studies, GB Pant University of Agriculture & Technology, Pantnagar and Indian Council of Agricultural Research, New Delhi for providing the necessary facilities/fund to carry out the study.

**Conflicts of interest**

The authors declared there is no conflict of interest.

**References**

1. Pappas G, Papadimitriou P, Akrigitis N, et al. The new global map of human brucellosis. *Lancet Infect Dis*. 2006;6(2):91–99.
2. Mantur BG, Amarnath S, Shinde RS. Review of clinical and laboratory features of human brucellosis. *Indian J Med Microbiol*. 2007;25(3):188–202.
3. Adams LG. The pathology of brucellosis reflects the outcome of the battle between the host genome and the *Brucella* genome. *Vet Microbiol*. 2002;90(1–4):553–561.
4. Radostits OM, Gay CC, Hinchcliff KW, et al. A textbook of the diseases of cattle, horses, sheep, pigs and goats. 10th ed. Elsevier Saunders: London, UK; 2007. p. 963–974.
5. OIE. Bovine brucellosis. In: Manual of diagnostic tests and vaccines for terrestrial animals; 2001(2):616–650.
6. Cutler SJ, Whatmore AM, Commander NJ. Brucellosis–new aspects of an old disease. *J Appl Microbiol*. 98(6):1270–1281.
7. Godfroid J, Nielsen K, Saegerman C. Diagnosis of brucellosis in livestock and wildlife. * Croat Med J*. 2010;51(4):296–305.
8. Amin AS, Handy ME, Ibrahim AK. Detection of *Brucella melitensis* in semen using the polymerase chain reaction assay. *Vet Microbiol*. 2001;83(1):37–44.
9. Hall WH. Modern chemotherapy for brucellosis in humans. *Rev Infect Dis*. 1990;12(6):1060–1099.
10. Gwatkin R, Macleod AH. Wheat germ oil in *Brucella* infection in cattle and Guinea pigs. *Can J Comp Med*. 1938;2(5):133–136.
11. Hall WH, Marion RE. In vitro susceptibility of *Brucella* to various antibiotics. *Appl Microbiol*. 1970;20(4):600–604.
12. Richardson M, Holt JN. Synergistic action of streptomycin with other antibiotics on intracellular *Brucella abortus* in vitro. *J Bacteriol*. 1962;84(4):638–646.
13. Dorsch M, Moreno E, Stackebrandt E. Nucleotide sequence of the 16S rRNA from *Brucella abortus*. *Nucleic Acids Res*. 1989;17(4):1765.
14. Alton GG, Jones LM, Pietz DE. Laboratory techniques in brucellosis. *Monogr Ser World Health Organ*. 1975;55(1):1–163.
15. Romero C, Pardo M, Grillo MJ, et al. Evaluation of PCR and indirect enzyme-linked immunosorbent assay on milk samples for diagnosis of brucellosis in dairy cattle. *J Clin Microbiol*. 1995;33(12):3198–3200.
16. Romero C, Lopez-Goni I. Improved method for purification of bacterial DNA from bovine milk for detection of *Brucella* spp. by PCR. *Appl Environ Microbiol*. 1999;65(8):3735–3737.
Assessment of haemato-biochemical parameters and therapeutics on brucella infected cattle.

17. Jain NC. Hematologic Techniques. In Schalm's Veterinary Hematology. 4th ed. Lea & Febiger: Philadelphia, USA; 1986. p. 20–48.
18. Snedecor GW, Cochrane WG. Statistical methods. 8th ed. Iowa State University Press: Ames, Iowa, USA; 1989.
19. Wadood F, Ahmad M, Khan A, et al. Seroprevalence of brucellosis in horses in and around Faisalabad. Pak Vet J. 2009;29(4):196–198.
20. Maadi H, Moharamnejad M, Haghi M. Prevalence of brucellosis in cattle in Urmia, Iran. Pak Vet J. 2011;31(1):81–82.
21. PD-ADMAS. National control program on brucellosis: aim and strategies. Hebbal: Bengaluru, India; 2012.
22. Patii CS, Hemashettar BM, Nagalothimath SJ. Prevalence of antibodies in sheep and goats of North Karnataka. 33rd Annual Conference of the Indian Association of Pathologists and Microbiologists: India; 1984.
23. Chandramohan CP, Ramadass P, Raghavan N. Studies on bovine brucellosis in an endemic area. Indian Vet J. 1992;69:581–583.
24. Saini SS, Sharma JK, Kwatra MS. Assessment of some management factors for prevalence of brucellosis among the traditionally managed animal population of Punjab. Indian J Anim Sci. 62(9):832–834.
25. Shakya S, Joshi RK, Ali SL, et al. Seroepidemiological survey of bovine brucellosis in a village of Madhya Pradesh. Indian Vet J. 1995;72(12):1327–1328.
26. Chahota R, Sharma M, Katooch RC, et al. Brucellosis outbreak in an organized dairy farm involving cows and in contact human beings, in Himachal Pradesh, India. Vet Arch. 2003;73(2):95–102.
27. Trangadia BJ, Rana SK, Mukherjee F, et al. Prevalence of brucellosis and infectious bovine rhinotracheitis in organized dairy farms in India. Trop Anim Hlth Prod. 2009;42(2):203–207.
28. Renukaradhya GJ, Isloor S, Rajasekhar M. Epidemiology, zoonotic aspects, vaccination and control/eradication of brucellosis in India. Vet Microbiol. 2002;90(1–4):183–195.
29. RAR. University of Minnesota, United States; 2011.
30. Sikder S, Rahman SMM, Alim MDA, et al. Haematological variations in Brucella abortus antibody positive cross-bred cattle at Chittagong, Bangladesh. YU Veteriner Fakultesi Dergisi. 2012;23(3):125–128.
31. Forbes LB, Tessaro SV, Lees W. Experimental studies on Brucella abortus in moose (Alces alces). J Wild Dis. 1996;32(1):94–104.
32. El-Boshy M, Abbas H, El-Khodery S, et al. Cytokine response and clinicopathological findings in Brucella infected camels (Camelus dromedarius). Veterinarni Medicina. 2009;54(1):25–32.
33. Enright FM, Walker JV, Jeffers G, et al. Cellular and humoral responses of Brucella abortus infected bovine fetuses. Am J Vet Res. 1984;45(3):424–430.
34. Omer SA, Al-Megrin WAI, Alagaili AN, et al. A new protocol for the treatment of Brucella melitensis in Neumann’s gazelle (Gazella elragleri) from Saudi Arabia using oxytetracycline and streptomycin. Afr J Biotechnol. 2011;10(53):11075–11080.
35. Hajia M, Rahbar M, Keramat F. Epidemiological, clinical, diagnostic and treatment aspects of hospitalized Brucellosis patients in Hamadan. Ann Trop Med Anim Hlth. 2009;2(2):42–45.
36. McCullough NB. Human brucellosis with special reference to the disease in the United States. Ann NY Acad Sci. 1958;70(3):541–556.
37. Spink WW. Current status of therapy of brucellosis in human beings. J Am Med Assoc. 1960;172:697–698.
38. Farid Z, Miale A, Omar MS, et al. Antibiotic treatment of acute brucellosis caused by Brucella melitensis. J Trop Med Hyg. 1961;64:157–162.

Citation: Kushwaha N, Rajora VS, Mohan A, et al. Assessment of haemato-biochemical parameters and therapeutics on brucella infected cattle. J Microbiol Exp. 2014;1(2):73–77. DOI: 10.15406/jmen.2014.01.00012